These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 18670241)

  • 1. Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir.
    Mahnke L; Child M; Satin L; Persson A; Bertz R; Lawrence J
    AIDS; 2008 Aug; 22(13):1698. PubMed ID: 18670241
    [No Abstract]   [Full Text] [Related]  

  • 2. Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
    Gianotti N; Guffanti M; Galli L; Margonato A; Chiaravalli G; Bigoloni A; Lazzarin A; Castagna A
    AIDS; 2007 Jul; 21(12):1648-51. PubMed ID: 17630564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus].
    Rivero A
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():1. PubMed ID: 20116609
    [No Abstract]   [Full Text] [Related]  

  • 4. Revised package insert for atazanavir.
    Sax PE
    AIDS Clin Care; 2008 Mar; 20(3):23. PubMed ID: 18399014
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug interactions. Atazanavir and acid-reducing agents.
    TreatmentUpdate; 2006; 18(3):4. PubMed ID: 17209238
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA notifications. Atazanavir capsule label is updated for pediatric patients.
    AIDS Alert; 2008 May; 23(5):59-60. PubMed ID: 18637262
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA notifications. Revised atazanavir package insert.
    AIDS Alert; 2008 Mar; 23(3):35-6. PubMed ID: 18661642
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA notifications. Alternative dosing regimen for atazanavir is approved.
    AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649
    [No Abstract]   [Full Text] [Related]  

  • 12. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 13. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
    Stebbing J; Nathan B; Jones R; McKenna A; Powles T; Bower M; Holmes P; Gazzard B; Nelson M
    AIDS; 2007 Aug; 21(13):1826-8. PubMed ID: 17690587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urolithiasis in HIV-positive patients treated with atazanavir.
    Couzigou C; Daudon M; Meynard JL; Borsa-Lebas F; Higueret D; Escaut L; Zucman D; Liotier JY; Quencez JL; Asselah K; May T; Neau D; Vittecoq D
    Clin Infect Dis; 2007 Oct; 45(8):e105-8. PubMed ID: 17879904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir: a novel inhibitor of HIV-protease in haemodialysis.
    Izzedine H; Launay-Vacher V; Peytavin G; Valantin MA; Deray G
    Nephrol Dial Transplant; 2005 Apr; 20(4):852-3. PubMed ID: 15772278
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
    Ly T; Ruiz ME
    Clin Infect Dis; 2007 Mar; 44(6):e67-8. PubMed ID: 17304444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New protease inhibitor against HIV. Viral load decreases--without lipid increase].
    MMW Fortschr Med; 2003 Aug; 145(33-34):61. PubMed ID: 14526586
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
    Grant P; Taylor J; Cain P; Short W; Gallant J; Farthing C; Thal G; Coakley E; Zolopa A
    Clin Infect Dis; 2009 Mar; 48(5):680-2. PubMed ID: 19191657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
    Chan-Tack KM; Truffa MM; Struble KA; Birnkrant DB
    AIDS; 2007 May; 21(9):1215-8. PubMed ID: 17502736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 96-week data from CASTLE study presented.
    Proj Inf Perspect; 2008 Dec; (47):3-4. PubMed ID: 19230058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.